John Camm, Hans Christop Diener - Debate: Are the new ESC guidelines too strict for LAA Occlusion?
John Camm, UK vs Hans Christoph Diener, DEU Debate: Are the new ESC guidelines are too strict for Left Atrial Appendage Occlusion? John Camm - Yes, they are too strict. There is a larger group that should benefit from LAA occlusion and it should be stronger recommended too!Hans Christoph Diener - No, the ESC guidelines are right; LAA occlusion Should be limited to OAC contraindicated patients!
Bernie Meier - Where are the patients for Left Atrial Appendage Occlusion therapy?
Introduction to discussion on patient selection and sources of referral, includes the clinical rationale and how to develop the referral channel.
Thorsten Lewalter - Where are the patients? At electrophysiology: PVI & LAAO
Includes the guidelines for the AF patients and the clinical rationale for combining or staging AF ablation and LAA occlusion therapy.
Jaime Masjuan - Where are the patients? At Neurology: patients with ischemic stroke on NOAC
The perspective from a neurologist on referring patients with a prior ischemic stroke on OAC or NOAC; is there a suitable patient population for left atrial appendage occlusion?
Antoine Lepillier - Where are the patients? At Gastroenterology: bleedings on NOAC
NOACs have a lower intra-cranial bleeding risk than Vitamine K antagonist. Yet, gastro-intestinal bleeding is higher. Therefore, are patients with recurrent GI-bleeds on NOAC candidate for left atrial appendage occlusion?
DJ Lakkireddy - Where are the patients? At the individual patient preference
What is the role of the patient? Who are the 'right' patients for LAA Occlusion, and is there future perspective for physicians interacting with patients directly requesting this therapy?
Patrick Serruys - Where are the patients | voting and closing Summit
Closure and final voting on patient selection and sources of referral, includes the clinical rationale and how to develop the referral channel.
Per Wester - NOACs; advances and limitations in real world
New oral anticoagulants or NOACs, with favorable results from large scale phase III clinical trials, represent a major advancement and expanded armamentarium in antithrombotic therapy. There are still limitations associated. Many patients in need of anticoagulant therapy for indications not studied in the clinical trials will not be eligible for treatment. The focus on NOACs has shifted to the practical approach and management in real life.
Holger Poppert - Stroke and bleeding risk stratification in AF from guideline to clinical practice
Broad based review, starting with the basic stroke risk management scores to bleeding risk scores towards expert knowledge and additional diagnostics to help define individual bleeding risk